0001161697-23-000441.txt : 20230809 0001161697-23-000441.hdr.sgml : 20230809 20230809161708 ACCESSION NUMBER: 0001161697-23-000441 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230809 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KORU Medical Systems, Inc. CENTRAL INDEX KEY: 0000704440 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133044880 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39086 FILM NUMBER: 231155408 BUSINESS ADDRESS: STREET 1: 100 CORPORATE DRIVE CITY: MAHWAH STATE: NJ ZIP: 07430 BUSINESS PHONE: 845-469-2042 MAIL ADDRESS: STREET 1: 100 CORPORATE DRIVE CITY: MAHWAH STATE: NJ ZIP: 07430 FORMER COMPANY: FORMER CONFORMED NAME: REPRO MED SYSTEMS INC DATE OF NAME CHANGE: 19920703 8-K 1 form_8-k.htm FORM 8-K CURRENT REPORT FOR AUGUST 9, 2023
0000704440 false 0000704440 2023-08-09 2023-08-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)   August 9, 2023

 

KORU Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 0-12305 13-3044880
(State or other jurisdiction
of incorporation)		 (Commission
File Number)		 (IRS Employer
Identification No.)

 

100 Corporate Drive, Mahwah, NJ 07430
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code   (845) 469-2042

 

______________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[_]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
common stock, $0.01 par value KRMD The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  [_]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

 

 

ITEM 2.02   RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

 

On August 9, 2023, KORU Medical Systems, Inc. (“KORU Medical” or “we”) issued a press release announcing its financial results for the second quarter ended June 30, 2023 and updates to full year financial outlook for the fiscal year ended December 31, 2023. A related conference call will be held on August 9, 2023 at 4:30 pm Eastern Time.

 

KORU Medical is making reference to non-GAAP financial measures in both the press release and the conference call. Our management believes that investors’ understanding of KORU Medical’s performance is enhanced by disclosing the non-GAAP financial measures of Adjusted EBITDA and Adjusted EPS (each as defined below) as a reasonable basis for comparison of our ongoing results of operations. KORU Medical strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by KORU Medical may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of GAAP to non-GAAP results is provided in the attached Exhibit 99.1 press release.

 

We define Adjusted EBITDA as earnings (net (loss)/income) before interest expense/(income), net, income tax (benefit)/expense, depreciation and amortization, reorganization charges, discontinued product expense, litigation expenses, manufacturing initiative expenses and stock-based compensation expense. We believe that Adjusted EBITDA is used by investors and other users of our financial statements as a supplemental financial measure that, when viewed with our GAAP results and the accompanying reconciliation, we believe provides additional information that is useful to gain an understanding of the factors and trends affecting our business. We also believe the disclosure of Adjusted EBITDA helps investors meaningfully evaluate and compare our cash flow generating capacity from quarter to quarter and year to year. Adjusted EBITDA is used by management as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual results against such expectations.

 

We present diluted earnings per share after eliminating items that we believe are not part of our ordinary operations and affect the comparability of the periods presented (“Adjusted EPS”). Adjusted EPS includes adjustments for reorganization charges, discontinued product expense, litigation expenses, manufacturing initiative expenses, stock-based compensation expense, and tax (expense). We believe adjustments for these items allow investors to better understand our underlying operating results and facilitate comparisons between the periods shown. Management uses Adjusted EPS as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual results against such expectations.

 

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits

 

Exhibit No. Description
   
99.1 Press release dated August 9, 2023
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

- 2 -

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  KORU Medical Systems, Inc.
(Registrant)
     
Date:  August 9, 2023 By: /s/ Thomas Adams
  Thomas Adams
Chief Financial Officer

 

- 3 -

 EX-99 2 ex_99-1.htm PRESS RELEASE DATED AUGUST 9, 2023

 

EXHIBIT 99.1

 

 

KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 SECOND QUARTER FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 OUTLOOK

 

MAHWAH, NJ – August 9, 2023 – KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the second quarter ended June 30, 2023 and updates full year 2023 outlook.

 

Highlights:

 

● Second quarter net revenue growth versus prior year of 6% to $6.9 million
   
● Domestic Core business growth of 8%, outperforming a second quarter U.S. script decline in subcutaneous immunoglobulin (SCIg) market, driven by strong volumes in consumables and pumps
   
● International Core business growth of 17%, driven by growth in several markets and increases in SCIg global drug availability
   
● Announced a new Novel Therapies collaboration for a Phase III study
   
● Submitted a 510(k) for FREEDOM60® Infusion System with Hizentra® 50 mL prefilled syringes
   
● Reduced 2023 net revenues guidance to $31.0 - $32.5 million, representing growth in the range of 11-17% from prior guidance of $32.5 - $33.5 million representing growth in the range of 17-20%
   
● Named Tom Adams as Chief Financial Officer

 

"I am pleased with our second quarter progress, as our growth exceeded the overall SCIg market in both the U.S. and Internationally," said Linda Tharby, KORU Medical's President and CEO. "The foundation of our business remains sound, and we are diligently focused on delivering above-market revenue performance, advancing our portfolio with our innovation efforts, and increasing the number of drugs on our Freedom Infusion System. We are excited to welcome Tom Adams as our Chief Financial Officer and look forward to his continued leadership contributions. We remain committed and on track to attain our Vision 2026 strategic goals, and deliver added value to patients, customers and shareholders."

 

2023 Second Quarter Financial Results

 

  Three Months
Ended June 30,		   Change from Prior Year
  2023   2022   $   %
Net Revenues                    
Domestic Core $ 5,388,172   $ 4,996,791   $ 391,381   $ 7.8%
International Core   1,117,004     951,485     165,519     17.4%
Novel Therapies   430,754     598,352     (167,598 )   (28.0)%
Total $ 6,935,930   $ 6,546,628   $ 389,302   $ 5.9%

 

Total net revenue increased $0.4 million, or 6%, for the three months ending June 30, 2023, compared to last year. Domestic Core growth of 8% was primarily driven by increased growth in consumables and pumps, new accounts, and increased prefilled syringe adoption. International Core growth of 17% was driven by strength across several EU markets, and growing global immunoglobulin drug volume availability. Novel Therapies net revenue declined by 28% in primarily related to strong non-recurring engineering revenues in the comparable quarter last year as well as the timing of 2023 pipeline wins.

 

 

Gross profit increased $0.5 million or 16% in the three months ended June 30, 2023, compared to the same period in 2022. The gross profit increase was driven by the rise in net revenue of $0.4 million, as described above. Gross profit as a percentage of revenue increased to 56.1% compared to 51.1% in the second quarter of 2022. The increase in the gross profit as a percentage of revenue was primarily driven by increased production efficiencies compared to the prior year.

 

Total operating expenses for the second quarter of 2023 were $7.1 million, compared to $7.0 million for the same period in 2022. The increase in operating expenses was primarily due to the impact of research and development costs in support of our innovation efforts.  

Net loss for the second quarter of 2023 was $2.5 million, or $(0.05) per diluted share, compared to a net loss of $2.9 million, or ($0.07) per diluted share for the same period of 2022. Net loss included a tax benefit of $0.6 million for the second quarter of 2023.

 

Assumptions and Outlook for Full Year 2023

 

KORU Medical updates prior guidance for 2023. The Company's guidance for full year 2023 has been updated to reflect a contraction in the underlying U.S. subcutaneous immunoglobulin market. KORU Medical is updating its 2023 growth outlook on the underlying U.S. subcutaneous immunoglobulin market to 5% from 10%. In addition, the Company’s guidance reflects a change in the timing of 2023 Novel Therapy deal signings.

 

KORU Medical Outlook:

 

● Reducing full year 2023 net revenue guidance to $31.0 and $32.5 million, representing growth in the range of 11%-17% from prior guidance of $32.5 - $33.5 million, representing growth in the range of 17-20%
   
● Reaffirming 2023 gross margin between 58%-60% and a planned 2023 exit between 60%-62%
   
● Reaffirming cash balance at year-end 2023 greater than $10.0 million

 

Conference Call and Webcast Details

 

The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Wednesday, August 9, 2023, at 4:30 PM ET.

 

To participate in the call, please dial (844) 826-3035 (domestic) or (412) 317-5195 (international) and provide conference ID: 10180800. The live webcast will be available on the IR Calendar on the News/Events page of the Investors section of KORU Medical's website.

 

Non-GAAP Measures

 

This press release includes the non-GAAP financial measures "Adjusted EBITDA" and "Adjusted Diluted Earnings Per Share" that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on KORU Medical's reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company's financial results. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. Reconciliations of the Company's non-GAAP measures are included at the end of this press release.

 

About KORU Medical Systems

 

KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

 

- 2 -

 

Forward-looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements, including, but not limited to, expected financial outlook and operating performance for fiscal 2023. Forward-looking statements discuss the Company's current expectations and projections relating to its financial position, results of operations, plans, objectives, future performance and business. Forward-looking statements can be identified by words such as "outlook", "expect", "plan", "believe" and "will". Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, uncertainties associated with the shift to increased healthcare delivery in the home, new patient diagnoses, customer ordering patterns, global health crises, innovation and competition, labor and supply price increases, inflationary impacts, labor supply, and those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, which are on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of August 9,2023. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

 

Investor Contact:

Greg Chodaczek

347-620-7010

investor@korumedical.com

 

- 3 -

 

KORU MEDICAL SYSTEMS, INC.

BALANCE SHEETS

(UNAUDITED)

 

           
    June 30,   December 31,  
    2023   2022  
               
ASSETS              
               
CURRENT ASSETS              
Cash and cash equivalents   $ 11,719,405   $ 17,408,257  
Accounts receivable less allowance for doubtful accounts of $21,459 as of June 30, 2023 and December 31, 2022     3,639,755     3,558,884  
Inventory     5,278,224     6,404,867  
Other receivables     1,131,115     972,396  
Prepaid expenses     772,893     1,457,232  
TOTAL CURRENT ASSETS     22,541,392     29,801,636  
Property and equipment, net     3,811,843     3,886,975  
Intangible assets, net of accumulated amortization of $357,809 and $325,872 as of June 30, 2023 and December 31, 2022, respectively     772,543     787,182  
Operating lease right-of-use assets     3,626,348     3,786,545  
Deferred income tax assets, net     5,144,876     3,967,480  
Other assets     98,970     102,625  
TOTAL ASSETS   $ 35,995,972   $ 42,332,443  
               
LIABILITIES AND STOCKHOLDERS’ EQUITY              
               
CURRENT LIABILITIES              
Accounts payable   $ 1,574,630   $ 2,391,799  
Accrued expenses     1,362,293     2,889,941  
Note payable     —     433,295  
Other liabilities     263,253     257,337  
Accrued payroll and related taxes     422,623     542,399  
Financing lease liability – current     101,072     98,335  
Operating lease liability – current     352,809     345,834  
TOTAL CURRENT LIABILITIES     4,076,680     6,958,940  
Financing lease liability, net of current portion     343,053     394,283  
Operating lease liability, net of current portion     3,475,092     3,653,257  
TOTAL LIABILITIES     7,894,825     11,006,480  
Commitments and Contingencies (Note 7)              
STOCKHOLDERS’ EQUITY              
Common stock, $0.01 par value, 75,000,000 shares authorized, 49,033,652 and 48,861,891 shares issued 45,613,150 and 45,441,389 shares outstanding as of June 30, 2023, and December 31, 2022, respectively     490,337     488,619  
Additional paid-in capital     45,932,354     44,252,117  
Treasury stock, 3,420,502 shares as of June 30, 2023 and December 31, 2022, at cost     (3,843,562 )   (3,843,562 )
Accumulated deficit     (14,477,982 )   (9,571,211 )
TOTAL STOCKHOLDERS’ EQUITY     28,101,147     31,325,963  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 35,995,972   $ 42,332,443  

 

The accompanying notes are an integral part of these financial statements.

 

- 4 -

 

KORU MEDICAL SYSTEMS, INC.

STATEMENTS OF OPERATIONS

(Unaudited)

 

                       
    Three Months Ended   Six Months Ended  
    June 30,   June 30,  
    2023   2022   2023   2022  
                           
NET REVENUES   $ 6,935,931   $ 6,546,628   $ 14,328,536   $ 12,790,958  
Cost of goods sold     3,047,807     3,200,455     6,293,377     5,822,480  
Gross Profit     3,888,124     3,346,173     8,035,159     6,968,478  
                           
OPERATING EXPENSES                          
Selling, general and administrative     5,303,167     5,530,022     10,729,044     11,021,235  
Research and development     1,596,614     1,303,731     3,161,483     2,452,086  
Depreciation and amortization     212,919     125,882     426,036     235,134  
Total Operating Expenses     7,112,700     6,959,635     14,316,563     13,708,455  
                           
Net Operating Loss     (3,224,576 )   (3,613,462 )   (6,281,404 )   (6,739,977 )
                           
Non-Operating Income/(Expense)                          
Loss on currency exchange     (2,472 )   (21,705 )   (3,152 )   (28,840 )
Loss on disposal of fixed assets, net     —     —     (56,279 )   —  
Interest income, net     131,167     3,566     256,669     2,103  
TOTAL OTHER INCOME/(EXPENSE)     128,695     (18,139 )   197,238     (26,737 )
                           
LOSS BEFORE INCOME TAXES     (3,095,881 )   (3,631,601 )   (6,084,166 )   (6,766,714 )
                           
Income Tax Benefit     599,995     710,260     1,177,395     1,307,859  
                           
NET LOSS   $ (2,495,886 ) $ (2,921,341 ) $ (4,906,771 ) $ (5,458,855 )
                           
NET LOSS PER SHARE                          
                           
Basic   $ (0.05 ) $ (0.07 ) $ (0.11 ) $ (0.12 )
Diluted   $ (0.05 ) $ (0.07 ) $ (0.11 ) $ (0.12 )
                           
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING                          
                           
Basic     45,606,603     44,921,870     45,547,427     44,795,625  
Diluted     45,606,603     44,921,870     45,547,427     44,795,625  

 

The accompanying notes are an integral part of these financial statements.

 

- 5 -

 

KORU MEDICAL SYSTEMS, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

             
    For the
Six Months Ended		  
    June 30,  
    2023   2022  
               
CASH FLOWS FROM OPERATING ACTIVITIES              
Net Loss   $ (4,906,771 ) $ (5,458,855 )
Adjustments to reconcile net loss to net cash used in operating activities:              
Stock-based compensation expense     1,681,955     1,579,151  
Depreciation and amortization     426,036     235,134  
Deferred income taxes     (1,177,395 )   (1,308,069 )
Loss on disposal of fixed assets     56,279     —  
ROU landlord credit     (10,994 )   —  
Changes in operating assets and liabilities:              
(Increase) in Accounts receivable     (239,590 )   (454,452 )
Decrease / (Increase) in Inventory     1,126,643     (665,176 )
Decrease in Prepaid expenses and other assets     687,994     334,193  
Increase in Other liabilities     5,916     150,501  
(Decrease) / Increase in Accounts payable     (817,169 )   1,162,329  
(Decrease) / Increase in Accrued payroll and related taxes     (119,776 )   535,438  
Decrease in Accrued expenses     (1,527,648 )   (735,508 )
NET CASH USED IN OPERATING ACTIVITIES     (4,814,520 )   (4,625,314 )
               
CASH FLOWS FROM INVESTING ACTIVITIES              
Purchases of property and equipment     (375,246 )   (1,915,289 )
Purchases of intangible assets     (17,298 )   (13,540 )
NET CASH USED IN INVESTING ACTIVITIES     (392,544 )   (1,928,829 )
               
CASH FLOWS FROM FINANCING ACTIVITIES              
Payments on indebtedness     (433,295 )   (508,583 )
Payments on finance lease liability     (48,493 )   (6,611 )
NET CASH USED IN FINANCING ACTIVITIES     (481,788 )   (515,194 )
               
NET DECREASE IN CASH AND CASH EQUIVALENTS     (5,688,852 )   (7,069,337 )
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD     17,408,257     25,334,889  
CASH AND CASH EQUIVALENTS, END OF PERIOD   $ 11,719,405   $ 18,265,552  
               
Supplemental Information              
Cash paid during the periods for:              
Interest   $ 20,165   $ 6,204  
Income taxes   $ 3,160   $ —  
               
Schedule of Non-Cash Operating, Investing and Financing Activities:              
Issuance of common stock as compensation   $ 266,023   $ 258,005  

 

The accompanying notes are an integral part of these financial statements.

 

- 6 -

 

KORU MEDICAL SYSTEMS, INC.

SUPPLEMENTAL INFORMATION

(UNAUDITED)

 

 

A reconciliation of our non-GAAP measures is below:

 

    Three Months Ended   Six Months Ended  
Reconciliation of GAAP Net (Loss)   June 30,   June 30,  
to Non-GAAP Adjusted EBITDA:   2023   2022   2023   2022  
GAAP Net Loss   $ (2,495,886 ) $ (2,921,341 ) $ (4,906,771 ) $ (5,458,855 )
Tax (Benefit)/Expense     (599,995 )   (710,260 )   (1,177,395 )   (1,307,859 )
Depreciation and Amortization     212,919     125,882     426,036     235,134  
Interest (Income)/Expense, Net     (131,168 )   (3,566 )   (256,669 )   (2,103 )
Reorganization Charges     —     270,433     —     565,433  
Manufacturing Initiative Expenses     6,308     50,344     55,361     88,349  
Stock-based Compensation Expense     800,734     821,513     1,681,956     1,659,070  
Non-GAAP Adjusted EBITDA   $ (2,207,088 ) $ (2,366,995 ) $ (4,177,482 ) $ (4,220,831 )

 

 

    Three Months Ended   Six Months Ended
Reconciliation of Reported Diluted EPS   June 30,   June 30,
to Non-GAAP Adjusted Diluted EPS:   2023   2022   2023   2022
Reported Diluted Earnings Per Share   $ (0.05 ) $ (0.07 ) $ (0.11 ) $ (0.12 )
Reorganization Charges     —     0.01     —     0.01  
Manufacturing Initiative Expenses     —     —     —     —  
Stock-based Compensation Expense     —     —     —     —  
Tax (Expense) Adjustment     —     —     —     —  
Non-GAAP Adjusted Diluted Earnings Per Share   $ (0.05 ) $ (0.06 ) $ (0.11 ) $ (0.11 )

 

*Numbers presented are rounded to the nearest whole cent

 

 

Reorganization Charges. We have excluded the effect of reorganization charges in calculating our non-GAAP measures.  In 2022 we incurred severance expenses related to the reorganization of the leadership team, which we would not have otherwise incurred in periods presented as part of continuing operations.

 

Manufacturing Initiative Expenses. We have excluded the effect of expenses related to creating manufacturing efficiencies, in calculating our non-GAAP measures. We incurred expenses in connection with these initiatives which we would not have otherwise incurred in periods presented as part of our continuing operations.

 

Stock-based Compensation Expense. We have excluded the effect of stock-based compensation expense in calculating our non-GAAP measures. We record non-cash compensation expenses related to grants of options and restricted shares for executives, employees and consultants, and grants of shares to our board of directors. Depending upon the size, timing and the terms of the grants, the non-cash compensation expense may vary significantly but will recur in future periods.

 

- 7 -

 GRAPHIC 3 koru_logo.jpg GRAPHIC begin 644 koru_logo.jpg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end EX-101.SCH 4 krmd-20230809.xsd INLINE XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 krmd-20230809_lab.xml INLINE XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 krmd-20230809_pre.xml INLINE XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 09, 2023
Entity File Number 0-12305
Entity Registrant Name KORU Medical Systems, Inc.
Entity Central Index Key 0000704440
Entity Tax Identification Number 13-3044880
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Corporate Drive
Entity Address, City or Town Mahwah
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07430
City Area Code 845
Local Phone Number 469-2042
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security common stock, $0.01 par value
Trading Symbol KRMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form_8-k_htm.xml IDEA: XBRL DOCUMENT 0000704440 2023-08-09 2023-08-09 iso4217:USD shares iso4217:USD shares 0000704440 false 8-K 2023-08-09 KORU Medical Systems, Inc. DE 0-12305 13-3044880 100 Corporate Drive Mahwah NJ 07430 845 469-2042 false false false false common stock, $0.01 par value KRMD NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://koru.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form_8-k.htm ex_99-1.htm krmd-20230809.xsd krmd-20230809_lab.xml krmd-20230809_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form_8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "form_8-k.htm" ] }, "labelLink": { "local": [ "krmd-20230809_lab.xml" ] }, "presentationLink": { "local": [ "krmd-20230809_pre.xml" ] }, "schema": { "local": [ "krmd-20230809.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "krmd", "nsuri": "http://koru.com/20230809", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "div", "body", "html" ], "baseRef": "form_8-k.htm", "contextRef": "AsOf2023-08-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://koru.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "div", "body", "html" ], "baseRef": "form_8-k.htm", "contextRef": "AsOf2023-08-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://koru.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001161697-23-000441-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001161697-23-000441-xbrl.zip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